News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

HemoBioTech, Inc. to Present Blood Substitute Strategy at RENN Capital Investor Conference



5/15/2009 10:20:59 AM

DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB:HMBT) (www.hemobiotech.com) announced today that Dr. Arthur P. Bollon, Chairman & CEO, will present the development strategy for its blood substitute, HemoTech, at the RENN Capital Investor Conference on May 15, 2009. Dr. Bollon will discuss the global need for a safe blood substitute as an alternative to contaminated blood. About 10% of new HIV/AIDS cases are due to HIV contaminated blood globally. RENN Capital is the leading institutional investor in HemoBioTech.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES